INmune Bio (INMB) Reports Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer - StreetInsider.com


6/16/2022 12:00:00 AM2 years 10 months ago

...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premiumhere. INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology compan… [+2894 chars]

full article...